Moleac is a certified Eco Office by the Singapore Environment Council
Moleac is excited to annouce that out Singapore office has been certified ECO-Office provided by...
NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries
Singapore, June 6, 2022, Moleac is pleased to announce the release of the results of the SATURN...
NeuroAiD™II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression
SINGAPORE, January 22 Moleac is pleased to announce the release of the ATHENE study results,...
Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals
SINGAPORE, MAY 2021 Moleac, a biopharmaceutical company based in Singapore, wins SBR National...
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery
SINGAPORE, APRIL 21 Moleac, a biopharmaceutical company based in Singapore, announced the approval...
ESOC 2020: Abstracts on NeuroAiD
In November 2020, ESO-WSO provided scientific updates to Health Care Practitioners. During this...
Embracing World Stroke Day 2020
World Stroke Day 2020 Stroke remains one of the main cause for disability worldwide. Moleac...
Highlights from Asia Pacific Stroke Organization (APSC) and World Congress of Neurology (WCN) Scientific Symposia
Two scientific symposia were conducted on the 2nd October 2019 and 29th October 2019. Multiple...
Highlights from European Stroke Organisation Conference (ESOC) Scientific Symposium
June 2019 A scientific symposium was held on the 24th May 2019, which aimed to share the advance...
Moleac holds two educational symposia on the management of Traumatic Brain Injury
March 2019 Moleac organized two symposia in Dubai and Bangkok on new approaches for Traumatic...
NeuroAiD combined with rehabilitation has shown additive and sustained benefits on post-stroke recovery over 2 years after an initial 3-month treatment following stroke onset
More subjects on NeuroAiD™ improved to functional independence compared to placebo among subjects...
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery
SINGAPORE, March 5, 2018 /PRNewswire/ — Moleac, a biopharmaceutical company focused on research...